Abstract
3027 Background: Human natural killer T (NKT) cells are activated by a specific ligand, α-Galactosylceramide (αGalCer) in a CD1d dependent manner. Previous findings showed that αGalCer-pulsed dendritic cells (DCs) exerted a strong antitumor activity in the mouse tumor metastatic models. With these results, we performed phase I/II study of αGalCer-pulsed dendritic cells in patients with advanced or recurrent non-small cell lung cancer (NSCLC) to obtain more findings about safety, immune responses and anti- tumor responses. Methods: Patients with advanced NSCLC or recurrent lung cancer refractory to the standard therapy were eligible. αGalCer-pulsed DCs (1x109/m2) were intravenously administered four times. Immune responses were monitored weekly by a flow cytometry analysis and an enzyme-linked immunospot assay. Additional follow-up was performed to clarify the prognosis and cause of death. Results: Twenty-three patients were enrolled in this study and 17 cases (73.9%) completed. No severe adverse event rel...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
